Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
Brain Research|January 2, 2007
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned ratsSarah Rose, Neil Ramsay Croft, Peter Jenner
The European Journal of Neuroscience|May 23, 2013
Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigraSara Ailane, Philip Long, Peter Jenner, et al.
The European Journal of Neuroscience|July 12, 2012
A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brainPhilip Long, Parwez Samnakay, Peter Jenner, et al.
The European Journal of Neuroscience|November 19, 2003
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCRMichael J Hurley, Deborah C Mash, Peter Jenner
International Review of Neurobiology|May 31, 2017
Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-DopaHee J Kim, Beom S Jeon, Peter Jenner
The European Journal of Neuroscience|May 28, 2011
Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned ratsMaria Papathanou, Sarah Rose, Andrew McCreary, et al.
Journal of Parkinson'S Disease|December 27, 2021
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and FutureYu-Yan Tan, Peter Jenner, Sheng-Di Chen
Journal of Neurochemistry|July 23, 2003
Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteinsDong-Hoon Hyun, MoonHee Lee, Barry Halliwell, et al.
Frontiers in Neurology|June 30, 2020
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-ViewpointCarolina Sportelli, Daniele Urso, Peter Jenner, et al.
Brain Research|August 4, 2010
The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brainSalma Bukhatwa, Bai-Yun Zeng, Sarah Rose, et al.
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
Brain Research|January 2, 2007
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned ratsSarah Rose, Neil Ramsay Croft, Peter Jenner
The European Journal of Neuroscience|May 23, 2013
Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigraSara Ailane, Philip Long, Peter Jenner, et al.
The European Journal of Neuroscience|July 12, 2012
A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brainPhilip Long, Parwez Samnakay, Peter Jenner, et al.
The European Journal of Neuroscience|November 19, 2003
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCRMichael J Hurley, Deborah C Mash, Peter Jenner
International Review of Neurobiology|May 31, 2017
Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-DopaHee J Kim, Beom S Jeon, Peter Jenner
The European Journal of Neuroscience|May 28, 2011
Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned ratsMaria Papathanou, Sarah Rose, Andrew McCreary, et al.
Journal of Parkinson'S Disease|December 27, 2021
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and FutureYu-Yan Tan, Peter Jenner, Sheng-Di Chen
Journal of Neurochemistry|July 23, 2003
Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteinsDong-Hoon Hyun, MoonHee Lee, Barry Halliwell, et al.
Frontiers in Neurology|June 30, 2020
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-ViewpointCarolina Sportelli, Daniele Urso, Peter Jenner, et al.
Brain Research|August 4, 2010
The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brainSalma Bukhatwa, Bai-Yun Zeng, Sarah Rose, et al.
Pageof 18